Article Sidebar
Views pdf: 25
HEPATITIS B SCREENING RESULTS ON OUT-CUSTOMERS AT TAM TRI SAI GON HOSPITAL IN 2023, EVALUATED ACCORDING TO CDC’S TRIPLE PANEL TEST, 2023
Main Article Content
Abstract
Aims: Hepatitis B screening results at Tam Tri Sai Gon Hospital in 2023 were evaluated according to a Triple Panel Test (HBsAg, anti-HBs and total anti-HBc) by the Center for Disease Control and Prevention (Centeres for Disease Control and Prevention: CDC) recommendations March 2023. Methods: Retrospective survey of 1439 people (patients: 766, health check-up people: 673) screened for hepatitis B, classified into groups: triple test (HBsAg, anti-HBs, total anti-HBc), double test (HBsAg, anti-HBs), single test set (HBsAg or anti-HBs). Odds ratio analysis with reference group as triple panel test. Results: There were 1439 cases of hepatitis B screening in 19167 customers (7.5%). Positive rate: HBsAg (74/1327: 5.58%); anti-HBs (275/638: 43.1%), total anti-HBc (6/12: 50%) and 1 case of negative HBc-IgM. Screened with triple test, n=10 (0.69%): 1 currently infected with HBV, 2 cured of HBV, 1 vaccinated with HBV, 4 susceptible to HBV, 2 isolated core anti-HBc positive. Screened with dual test, n=516 (35.86%): 28 currently infected with HBV (5.4%), 2 were co-positive for HBsAg and anti-HBs (0.4%), and 486 were unexplained (94.2%). The unexplained odds ratio for the dual test compared to triple test was 172 (p= 0.01). Screened with 1 test alone, n= 799 for HBsAg (55.52%) and 112 for anti-HBs (7.78%): 100% of cases were unexplained, Odds ratio were 8800 (p= 0.0001) and 1243 (p= 0.0001) and 1243 ( p=0.0001) when compared with the triple test accordingly. Conclusion: There was only triple panel test (triple panel test) that helps screen HBV completely and accurately. Testing alone with HBsAg or anti-HBs is contraindicated because it is uninterpretable and expensive for customers.
Article Details
Keywords
Hepatitis B, isolated core anti-HBc positive, coexistence of HBsAg and antiHBs,
References
2. Erin E. Conners, Lakshmi Panagiotakopoulos, Megan G. Hofmeister, et al. Screening and Testing for Hepatitis B Virus Infection: CDC Recommendations — United States, 2023. MMWR Recomm Rep. March 10, 2023;Volume 72, N.1:1-25.
3. Nguyen Thi Cam Huong, Hoang Anh Vu, Bac An Luong, et al. The Coexistence of Hepatitis B Surface Antigen and Anti-HBs in Patients With Chronic HBV Infection: Prevalence and Related Factors. Gastro Hep Advances 2023;2:467–474
4. Catherine Freeland, Vivek Sreepathi, Richard W. Hass, et al. The importance of triple panel testing for hepatitis B and the burden of isolated anti-hepatitis B core antibodies within a community sample. Journal of Virus Eradication 9 (2023) 100358. https://doi.org/10.1016/j.jve.2023.100358
5. Shreyasi Athalye, Amruta Patil, Naveen Khargekar, et al. Effcacy of combined HBsAg, anti-HBc and anti-HBs screening in minimizing transfusion transmission risk of hepatitis B infection in low resource setting. Heliyon 10 (2024) e25805 https://doi.org/10.1016/j.heliyon.2024.e25805
6. Chengwei Wang, Xiaoqin Li, Chuanmeng Zhang , Li Xiao & Jianchun Xian. Prevalence and infuential factors of isolated hepatitis B core antibody positivity in a Chinese adult population. Scientifc Reports | (2024) 14:693. https://doi.org/10.1038/s41598-023-50907-6.
7. Hyun CS, Lee S, Ventura WR. The prevalence and signifcance of isolated hepatitis B core antibody (anti-HBc) in endemic population. BMC Res Notes. 2019;12(1).https:// doi.org/10.1186/s13104-019-4287-z.
8. Lee BS, Cho YK, Jeong SH, et al. Nationwide seroepidemiology of hepatitis B virus infection in South Korea in 2009 emphasizes the coexistence of HBsAg and antiHBs. J Med Virol 2013;85(8):1327–1333.